Altimmune (ALT) Projected to Post Earnings on Tuesday

Key Points

• Altimmune is scheduled to report Q1 2026 results before the market opens on May 12, 2026, with analysts modeling EPS of ($0.25) and revenue of about $0.001 million.
• Analysts have a mixed view but a consensus rating of Moderate Buy and an average price target of $18.00, though firms like B. Riley recently cut their target to $13 and other brokers have issued buy, hold and sell opinions.

Altimmune (NASDAQ:ALT - Get Free Report) is expected to release its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Altimmune to post earnings of ($0.25) per share and revenue of $0.0010 million for the quarter. Interested persons may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:30 AM ET.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.02). Altimmune had a negative return on equity of 49.35% and a negative net margin of 214,860.98%.The firm had revenue of $0.03 million for the quarter, compared to analysts' expectations of $0.00 million. On average, analysts expect Altimmune to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Altimmune Price Performance

Shares of ALT traded up $0.03 during midday trading on Tuesday, hitting $3.05. 2,072,482 shares of the company traded hands, compared to its average volume of 4,610,475. The stock has a 50-day moving average of $3.50 and a 200-day moving average of $4.16. Altimmune has a one year low of $2.56 and a one year high of $7.73. The firm has a market cap of $396.17 million, a P/E ratio of -3.00 and a beta of 0.18. The company has a debt-to-equity ratio of 0.15, a current ratio of 18.55 and a quick ratio of 18.55.

Insider Activity

In related news, CEO Jerome Benedict Durso acquired 20,000 shares of the business's stock in a transaction that occurred on Friday, March 6th. The stock was bought at an average cost of $3.54 per share, for a total transaction of $70,800.00. Following the purchase, the chief executive officer owned 32,500 shares in the company, valued at $115,050. The trade was a 160.00% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 1.60% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Altimmune by 4.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company's stock worth $247,000 after purchasing an additional 2,241 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in Altimmune in the 1st quarter worth approximately $50,000. Envestnet Asset Management Inc. lifted its holdings in Altimmune by 48.0% in the 2nd quarter. Envestnet Asset Management Inc. now owns 32,908 shares of the company's stock worth $127,000 after purchasing an additional 10,671 shares in the last quarter. Creative Planning lifted its holdings in Altimmune by 30.2% in the 2nd quarter. Creative Planning now owns 41,164 shares of the company's stock worth $159,000 after purchasing an additional 9,558 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in Altimmune by 7.0% in the 2nd quarter. Rhumbline Advisers now owns 113,981 shares of the company's stock worth $441,000 after purchasing an additional 7,462 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ALT. B. Riley Financial decreased their price target on Altimmune from $18.00 to $13.00 and set a "buy" rating on the stock in a research report on Friday, March 6th. Wall Street Zen cut shares of Altimmune from a "hold" rating to a "sell" rating in a research report on Saturday, March 7th. William Blair restated a "market perform" rating on shares of Altimmune in a research report on Thursday, March 5th. Truist Financial assumed coverage on shares of Altimmune in a research report on Wednesday, March 18th. They issued a "buy" rating and a $12.00 price objective on the stock. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Altimmune in a research report on Friday, March 27th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $18.00.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune's approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.